indazoles has been researched along with Necrosis in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (6.67) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 8 (53.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bronk, SF; Gores, GJ; Hernandez, MC; Hirsova, P; Kabashima, A; Kaufmann, SH; Rizvi, S; Truty, MJ | 1 |
| Fulda, S | 1 |
| Fujisawa, M; Hinata, N; Jimbo, N; Shigemura, K; Shiraishi, Y; Terakawa, T | 1 |
| Amantini, C; Berardi, R; Bonfili, L; Burattini, L; Cascinu, S; Eleuteri, AM; Farfariello, V; Liberati, S; Morelli, MB; Mozzicafreddo, M; Nabissi, M; Santoni, G; Santoni, M | 1 |
| Bennett, KL; Bigenzahn, JW; Bruckner, M; Colinge, J; Fauster, A; Gridling, M; Huber, KV; Krautwald, S; Kubicek, S; Lardeau, CH; Linkermann, A; Parapatics, K; Rebsamen, M; Scorzoni, S; Stukalov, A; Superti-Furga, G | 1 |
| Demizu, Y; Futani, H; Mohri, T; Okimoto, T; Sakagami, M; Terada, T; Tsukamoto, Y; Uwa, N | 1 |
| Amantini, C; Bernardini, G; Cardinali, C; Morelli, MB; Nabissi, M; Santoni, A; Santoni, G; Santoni, M | 1 |
| Choi, S; Cuny, GD; Degterev, A; Keys, H; Staples, RJ; Yuan, J | 1 |
| Aoki, MS; Miyabara, EH; Moriscot, AS; Selistre-de-Araújo, HS; Tostes, RC | 1 |
| Bhatia, M; Chevali, L; Guglielmotti, A; Ramnath, RD | 1 |
| Choi, S; Cuny, GD; Degterev, A; Jagtap, PG; Keys, H; Yuan, J | 1 |
| Dunn, D; Farnworth, M; Gyte, A; Lock, EA; Moore, RB; Simpson, MG; Widdowson, PS; Wyatt, I | 1 |
| Dowsing, B; Guida, E; Hickey, MJ; Knight, KR; Morrison, WA; Phan, LH; Stewart, AG; Zhang, B | 1 |
| Hsueh, W; Zhang, C | 1 |
| Boranić, M; Gajsak, V; Jercić, J; Lelieveld, P; Mihalić, H; Radacić, M; Skarić, D; Skarić, V | 1 |
1 review(s) available for indazoles and Necrosis
| Article | Year |
|---|---|
Repurposing anticancer drugs for targeting necroptosis.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Drug Repositioning; Humans; Imidazoles; Indazoles; Necrosis; Oximes; Pyridazines; Pyrimidines; Reperfusion Injury; Sorafenib; Sulfonamides; Systemic Inflammatory Response Syndrome; Vemurafenib | 2018 |
14 other study(ies) available for indazoles and Necrosis
| Article | Year |
|---|---|
Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Cell Death; Cell Line, Tumor; Cholangiocarcinoma; Humans; Indazoles; Indoles; Male; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Necrosis; Oxidation-Reduction; Receptors, Fibroblast Growth Factor; Sulfonamides; Xenograft Model Antitumor Assays | 2018 |
Total necrosis after sequential treatment with pazopanib followed by nivolumab in a patient with renal cell carcinoma involving the inferior vena cava.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Humans; Indazoles; Kidney; Kidney Neoplasms; Necrosis; Neoadjuvant Therapy; Neoplasm Invasiveness; Nephrectomy; Nivolumab; Pyrimidines; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior | 2019 |
Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Membrane Potential, Mitochondrial; Necrosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reactive Oxygen Species; Sulfonamides; Sunitinib; Urinary Bladder Neoplasms | 2013 |
A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.
Topics: 3T3 Cells; Animals; Apoptosis; Cell Line, Tumor; Fas-Associated Death Domain Protein; HEK293 Cells; HT29 Cells; Humans; Imidazoles; Indazoles; Jurkat Cells; L Cells; MAP Kinase Kinase Kinases; Mice; Necrosis; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Pyridazines; Pyrimidines; Receptor-Interacting Protein Serine-Threonine Kinases; Sulfonamides; Tumor Necrosis Factor-alpha | 2015 |
An unexpected skin ulcer and soft tissue necrosis after the nonconcurrent combination of proton beam therapy and pazopanib: A case of myxofibrosarcoma.
Topics: Angiogenesis Inhibitors; Debridement; Fatal Outcome; Fibrosarcoma; Head and Neck Neoplasms; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Myxoma; Necrosis; Proton Therapy; Pyrimidines; Skin Ulcer; Soft Tissue Infections; Sulfonamides; Tomography, X-Ray Computed | 2017 |
Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner.
Topics: Axitinib; Bortezomib; Cell Death; Cell Line, Tumor; Cell Survival; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Gene Expression; Glioma; Humans; Imidazoles; Indazoles; Mitosis; Necrosis; Proteasome Inhibitors; Protein Kinase Inhibitors; Reactive Oxygen Species; Signal Transduction | 2017 |
Optimization of tricyclic Nec-3 necroptosis inhibitors for in vitro liver microsomal stability.
Topics: Animals; Drug Stability; Humans; Indazoles; Jurkat Cells; Mice; Microsomes, Liver; Models, Molecular; Necrosis; Pyrazoles; Structure-Activity Relationship | 2012 |
Role of nitric oxide in myotoxic activity induced by crotoxin in vivo.
Topics: Analysis of Variance; Animals; Brazil; Crotalus; Crotoxin; Guanidines; Histological Techniques; Indazoles; Muscle, Skeletal; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Rats; Rats, Wistar; Signal Transduction | 2004 |
Treatment with bindarit, a blocker of MCP-1 synthesis, protects mice against acute pancreatitis.
Topics: Acute Disease; Animals; Ceruletide; Chemokine CCL2; Disease Models, Animal; Indazoles; Inflammation; Mice; Necrosis; Pancreas; Pancreatitis; Propionates | 2005 |
Structure-activity relationship study of tricyclic necroptosis inhibitors.
Topics: Caspases; Cell Line; Fas-Associated Death Domain Protein; Heterocyclic Compounds, 3-Ring; Humans; Indazoles; Necrosis; Pyrazoles; Stereoisomerism; Structure-Activity Relationship; Tumor Necrosis Factor-alpha | 2007 |
Possible role of nitric oxide in the development of L-2-chloropropionic acid-induced cerebellar granule cell necrosis.
Topics: Animals; Aspartic Acid; Cerebellum; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; Hydrocarbons, Chlorinated; In Vitro Techniques; Indazoles; Male; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitroarginine; Ornithine; Propionates; Rats | 1996 |
Timing of administration of dexamethasone or the nitric oxide synthase inhibitor, nitro-L-arginine methyl ester, is critical for effective treatment of ischaemia-reperfusion injury to rat skeletal muscle.
Topics: Animals; Anti-Inflammatory Agents; Dexamethasone; DNA Probes; Enzyme Inhibitors; Indazoles; Isothiuronium; Male; Muscle, Skeletal; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Ornithine; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Time Factors | 1997 |
PAF-induced bowel necrosis. Effects of vasodilators.
Topics: Alprostadil; Animals; Hydralazine; Hypotension; Indazoles; Intestinal Diseases; Leukopenia; Male; Mesenteric Arteries; Necrosis; Nitroglycerin; Phenoxybenzamine; Platelet Activating Factor; Prazosin; Rats; Rats, Inbred Strains; SRS-A; Vasodilator Agents | 1991 |
Reduction of cis-dichlorodiammineplatinum(II) caused nephrotoxicity by indazolone carboxylic acid.
Topics: Animals; Blood Urea Nitrogen; Body Weight; Cell Division; Cell Survival; Cisplatin; Indazoles; Kidney; Kidney Diseases; Leukemia L1210; Male; Mice; Mice, Inbred CBA; Necrosis; Pyrazoles | 1987 |